Rheumatoid Arthritis Research Today is a free monthly online journal that collates and summarizes the latest research about Rheumatoid Arthritis, including details on treatment, symptoms, causes, medication.

Volume 2 (2005), Issue 2 (February)

1. Validity of reported energy expenditure and reported intake of energy, protein, sodium and potassium in rheumatoid arthritis patients in a dietary intervention study.
   Eur J Clin Nutr, 59(2): 238-45. [Abstract] [Full-text]
2. Acute hypoxic respiratory failure as the first manifestation of systemic-onset juvenile rheumatoid arthritis in a child.
   Pediatr Pulmonol, 38(6): 483-7. [Abstract] [Full-text]
3. Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis.
   Semin Arthritis Rheum, 34(4): 668-77. [Abstract] [Full-text]
4. Rheumatoid arthritis in American Indians and Alaska Natives: a review of the literature.
   Semin Arthritis Rheum, 34(4): 662-7. [Abstract] [Full-text]
5. Why Atlas, why not Heracles: reflections on the rheumatoid cervical spine.
   Semin Arthritis Rheum, 34(4): 637-41. [Abstract] [Full-text]
6. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
   J Am Acad Dermatol, 52(2): 262-7. [Abstract] [Full-text]
7. Potential involvement of subclinical Sjögren's syndrome in various lung diseases.
   Respirology, 10(1): 86-91. [Abstract] [Full-text]
8. Comparative modeling of TNFRSF25 (DR3) predicts receptor destabilization by a mutation linked to rheumatoid arthritis.
   Biochem Biophys Res Commun, 328(3): 794-9. [Abstract] [Full-text]
9. TNF-alpha modulates angiopoietin-1 expression in rheumatoid synovial fibroblasts via the NF-kappa B signalling pathway.
   Biochem Biophys Res Commun, 328(2): 409-14. [Abstract] [Full-text]
10. Autoimmune hepatitis in primary Sjogren's syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren's syndrome.
    Pathol Int, 55(2): 70-6. [Abstract] [Full-text]
11. Autoimmunity against a tissue kallikrein in IQI/Jic Mice: a model for Sjogren's syndrome.
    J Biol Chem, 280(5): 3982-8. [Abstract] [Full-text]
12. Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control.
    Curr Med Res Opin, 20(12): 1967-77. [Abstract] [Full-text]
13. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.
    Arthritis Rheum, 52(2): 402-11. [Abstract] [Full-text]
14. Identification of the epidermal growth factor-TM7 receptor EMR2 and its ligand dermatan sulfate in rheumatoid synovial tissue.
    Arthritis Rheum, 52(2): 442-50. [Abstract] [Full-text]
15. SLC22A4 polymorphisms implicated in rheumatoid arthritis and Crohn's disease are not associated with rheumatoid arthritis in a Canadian Caucasian population.
    Arthritis Rheum, 52(2): 425-9. [Abstract] [Full-text]
16. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Arthritis Rheum, 52(2): 548-53. [Abstract] [Full-text]
17. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
    Arthritis Rheum, 52(2): 554-62. [Abstract] [Full-text]
18. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years.
    Arthritis Rheum, 52(2): 412-20. [Abstract] [Full-text]
19. Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis.
    Arthritis Rheum, 52(2): 430-41. [Abstract] [Full-text]
20. Reduction of joint damage in severe rheumatoid arthritis by high-dose chemotherapy and autologous stem cell transplantation.
    Arthritis Rheum, 52(2): 421-4. [Abstract] [Full-text]
21. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results.
    Arthritis Rheum, 52(2): 563-72. [Abstract] [Full-text]
22. Novel role of CD40 in Fas-dependent apoptosis of cultured salivary epithelial cells from patients with Sjögren's syndrome.
    Arthritis Rheum, 52(2): 573-81. [Abstract] [Full-text]
23. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor.
    Arthritis Rheum, 52(2): 451-60. [Abstract] [Full-text]
24. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    Arthritis Rheum, 52(2): 582-91. [Abstract] [Full-text]
25. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
    Arthritis Rheum, 53(1): 18-23. [Abstract] [Full-text]
26. Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists.
    Arthritis Rheum, 53(1): 12-7. [Abstract] [Full-text]
27. Fatigue in patients with ankylosing spondylitis: A comparison with the general population and associations with clinical and self-reported measures.
    Arthritis Rheum, 53(1): 5-11. [Abstract] [Full-text]
28. Cost-utility and cost-effectiveness analyses of a long-term, high-intensity exercise program compared with conventional physical therapy in patients with rheumatoid arthritis.
    Arthritis Rheum, 53(1): 39-47. [Abstract] [Full-text]
29. Disease activity measurement of rheumatoid arthritis: Comparison of the simplified disease activity index (SDAI) and the disease activity score including 28 joints (DAS28) in daily routine.
    Arthritis Rheum, 53(1): 56-60. [Abstract] [Full-text]
30. Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel.
    Arthritis Rheum, 53(1): 61-6. [Abstract] [Full-text]
31. Comprehensive assessment of clinical outcome and quality of life after total elbow arthroplasty.
    Arthritis Rheum, 53(1): 73-82. [Abstract] [Full-text]
32. Physical activity, physical fitness, and general health perception among individuals with rheumatoid arthritis.
    Arthritis Rheum, 53(1): 48-55. [Abstract] [Full-text]
33. Radiographic progression in children with polyarticular juvenile rheumatoid arthritis: a pilot study.
    Ann Rheum Dis, 64(3): 491-3. [Abstract] [Full-text]
34. B cell MALT lymphoma diagnosed by labial minor salivary gland biopsy in patients screened for Sjögren's syndrome.
    Ann Rheum Dis, 64(3): 471-3. [Abstract] [Full-text]
35. Analysis of the insertion/deletion related polymorphism within T cell antigen receptor beta variable genes in primary Sjögren's syndrome.
    Ann Rheum Dis, 64(3): 468-70. [Abstract] [Full-text]
36. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography.
    Ann Rheum Dis, 64(3): 375-81. [Abstract] [Full-text]
37. Etanercept in arthritis.
    Int J Clin Pract, 59(1): 114-8. [Abstract] [Full-text]
38. Primary Sjögren's syndrome: new clinical and therapeutic concepts.
    Ann Rheum Dis, 64(3): 347-54. [Abstract] [Full-text]
39. Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis.
    Ann Rheum Dis, 64(3): 368-74. [Abstract] [Full-text]
40. Galectin-3 is induced in rheumatoid arthritis synovial fibroblasts after adhesion to cartilage oligomeric matrix protein.
    Ann Rheum Dis, 64(3): 419-24. [Abstract] [Full-text]
41. Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis.
    Ann Rheum Dis, 64(3): 487-90. [Abstract] [Full-text]
42. Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors.
    Ann Rheum Dis, 64(3): 359-67. [Abstract] [Full-text]
43. Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity.
    Ann Rheum Dis, 64(3): 433-7. [Abstract] [Full-text]
44. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
    Ann Rheum Dis, 64(3): 403-7. [Abstract] [Full-text]
45. Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity.
    Ann Rheum Dis, 64(3): 415-8. [Abstract] [Full-text]
46. Lower limb arterial incompressibility and obstruction in rheumatoid arthritis.
    Ann Rheum Dis, 64(3): 425-32. [Abstract] [Full-text]
47. Inhibition of TNF alpha during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNF alpha blockade in rheumatoid arthritis.
    Ann Rheum Dis, 64(3): 408-14. [Abstract] [Full-text]
48. Analysis of the functional NFKB1 promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus.
    Tissue Antigens, 65(2): 183-6. [Abstract] [Full-text]
49. Validity of stimulated whole saliva collection as a sialometric evaluation for diagnosing Sjögren's syndrome.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 99(3): 299-302. [Abstract] [Full-text]
50. An unusual cause of difficult intubation in a patient with a large cervical anterior osteophyte: a case report.
    Acta Anaesthesiol Scand, 49(2): 264-6. [Abstract] [Full-text]
51. Expression of aquaporin-5 in and fluid secretion from immortalized human salivary gland ductal cells by treatment with 5-aza-2'-deoxycytidine: a possibility for improvement of xerostomia in patients with Sjögren's syndrome.
    Lab Invest, 85(3): 342-53. [Abstract] [Full-text]
52. Overlapping gene expression profiles in rheumatoid fibroblast-like synoviocytes induced by the proinflammatory cytokines interleukin-1 beta and tumor necrosis factor.
    Inflamm Res, 54(1): 10-6. [Abstract] [Full-text]
53. A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis.
    Inflamm Res, 54(1): 1-9. [Abstract] [Full-text]
54. Epstein-Barr virus etiology in rheumatoid synovitis.
    Autoimmun Rev, 4(2): 106-10. [Abstract] [Full-text]
55. Fractal analysis of acceleration signals from patients with CPPD, rheumatoid arthritis, and spondyloarthroparthy of the finger joint.
    Comput Methods Programs Biomed, 77(3): 233-9. [Abstract] [Full-text]
56. Effects of emotional disclosure on psychological and physiological outcomes in patients with rheumatoid arthritis: an exploratory home-based study.
    J Health Psychol, 10(2): 277-85. [Abstract] [Full-text]
57. Tumor necrosis factor-alpha -308 promoter polymorphism contributes independently to HLA alleles in the severity of rheumatoid arthritis in Mexicans.
    J Autoimmun, 24(1): 63-8. [Abstract] [Full-text]
58. A peptide of human muscarinic acetylcholine receptor 3 is antigenic in primary Sjogren's syndrome.
    J Autoimmun, 24(1): 47-54. [Abstract] [Full-text]
59. Regulated and constitutive expression of anti-inflammatory cytokines by nontransforming herpesvirus saimiri vectors.
    Gene Ther, 12(5): 395-406. [Abstract] [Full-text]
60. Epidural hematoma unrelated to combined spinal-epidural anesthesia in a patient with ankylosing spondylitis receiving aspirin after total hip replacement.
    Anesth Analg, 100(3): 882-3, table of contents. [Abstract] [Full-text]
61. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis.
    Osteoarthritis Cartilage, 13(3): 258-65. [Abstract] [Full-text]
62. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles.
    Proc Natl Acad Sci U S A, 102(8): 2892-7. [Abstract] [Full-text]
63. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus.
    Rheumatology (Oxford), 44(3): 280-6. [Abstract] [Full-text]
64. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome.
    Rheumatology (Oxford), 44(3): 323-31. [Abstract] [Full-text]
65. The patient's perspective and rheumatoid arthritis disease activity indexes.
    Rheumatology (Oxford), 44(3): 360-5. [Abstract] [Full-text]
66. The inhibition of antithrombin by peptidylarginine deiminase 4 may contribute to pathogenesis of rheumatoid arthritis.
    Rheumatology (Oxford), 44(3): 293-8. [Abstract] [Full-text]
67. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Rheumatology (Oxford), 44(3): 342-8. [Abstract] [Full-text]
68. Efficacy of rapamycin in patient with juvenile rheumatoid arthritis.
    Transpl Int, 18(3): 366-8. [Abstract] [Full-text]
69. IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin.
    Clin Exp Immunol, 139(3): 542-50. [Abstract] [Full-text]
70. Essential roles of Toll-like receptor-4 signaling in arthritis induced by type II collagen antibody and LPS.
    Int Immunol, 17(3): 325-33. [Abstract] [Full-text]

© 2004-2008 Rheumatoid Arthritis Research Today. All Rights Reserved.